The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.50
Bid: 45.00
Ask: 46.00
Change: -1.00 (-2.15%)
Spread: 1.00 (2.222%)
Open: 46.50
High: 45.50
Low: 45.00
Prev. Close: 46.50
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: European Equities Slip Amid Inflation Fears

Mon, 22nd Feb 2021 08:47

(Alliance News) - Stock prices in Europe started the new week on a low ebb with sentiment damped by concerns that an acceleration in inflation could spell an end to stimulus measures.

In the UK, focus will be on Prime Minister Boris Johnson, who is set to present a roadmap to exit lockdown in England.

The flagship FTSE 100 index was down 51.02 points, or 0.8%, at 6,573.00 early Monday. The domestic-focused FTSE 250 index was down 212.49 points, or 1.0%, at 20,823.47, and the AIM All-Share index was down 7.34 points, or 0.6%, at 1,206.84.

The Cboe UK 100 index was down 1.3% at 652.33 points. The Cboe 250 was down 1.1% at 18,388.39, but the Cboe Small Companies was marginally higher at 12,801.41.

The CAC 40 index in Paris was down 0.8% and Frankfurt's DAX 30 was 0.9% lower.

"It's one of these days where investors don't know what to do with the good news. Asian markets kicked off the week on a flat-to-negative note despite the most-expected news that the immunization with Pfizer and BioNTech's Covid vaccines do curtail the transmission of the coronavirus. In other words, it means that the Covid vaccines will actually be the game changer in 2021," Swissquote analyst Ipek Oykardeskaya commented.

"But it also means that the huge monetary and fiscal stimulus will be harder to justify, and companies will need to fly with their own wings. The major worry is that the rising inflation worries could accelerate the end of the stimulus game."

In London, miner and commodities broker Glencore was among the better-performing large-caps stocks, up 1.2%. JPMorgan raised Glencore to Overweight from Neutral.

International Consolidated Airlines Group climbed 0.4% as the British Airways parent announced the UK flag carrier has secured two finance-support pacts worth GBP2.45 billion in total.

BA has secured a GBP2.0 billion UK Export Development Guarantee of GBP2.0 billion. The term-loan is for five years. British Airways also agreed a deferral of GBP450 million in pension deficit contributions that were due from October last year to September this year.

Among mid-caps, Mitchells & Butlers fell 1.3% as it noted a sharp fall in sales in recent months and launched an open offer to bolster the pub operator's finances.

Mitchells & Butlers announced a GBP351 million open offer of shares to bolster its balance sheet as its "liquidity position has deteriorated significantly as a result of the impact of the Covid-19 pandemic".

The All Bar One owner said the extra cash will go towards reducing its unsecured debt. It also will support its secured debt financing.

Since the end of December, none of M&B's sites have been open. In the period between, September 27 and January 16, total managed sales were 70% lower annually.

Pubs, airlines and the wider travel & leisure industry will be in focus Monday as UK PM Johnson outlines how the Covid-19 curbs will be eased, paving the way for the first easing of restrictions since England's third national lockdown was announced on January 4.

All pupils in all years can go back to the classroom from March 8, with outdoor after-school sports and activities allowed to restart as well, Johnson is expected to say.

Socialising in parks and public spaces with one other person also will be permitted in a fortnight when the rules are relaxed to allow people to sit down for a drink or picnic.

However, Number 10 insisted that the "stay at home" message would remain in place despite the relaxation of some restrictions.

Sterling slipped below the USD1.40 mark as the dollar was higher across the board early Monday. The pound was quoted at USD1.3996, down slightly from USD1.4020 at the London equities close Friday.

The euro also lost ground on the dollar over the weekend. The euro stood at USD1.2104 early Monday, down from USD1.2139 at the European equities close Friday. Against the yen, the dollar was trading at JPY105.79, improved from JPY105.53.

Back in London, fund supermarket Hargreaves Lansdown and trading platform AJ Bell were down 0.9% and 1.9%, respectively.

AJ Bell, Hargreaves Lansdown, and Interactive Investor have all written to the UK Treasury complaining about their exclusion from a majority of initial public offerings.

The heads of the three companies wrote to City minister John Glen last week asking that he consider forcing companies to consider retail offers in new flotations as well as the opening of a wider consultation.

The letter noted that smaller investors has been unable to buy into the recent IPOs from online personalised cards and gifts retailer Moonpig Group, as well as shoe maker Dr Martens and Hut Group owner THG.

In all three cases, share prices for the companies rose to an instant premium to the IPO price, forcing private investors to pay more hefty amounts for shares.

"As it stands, retail shareholder rights are almost completely ignored when it comes to the vast majority of IPOs, which largely take place between City institutions behind closed doors," the letter said.

Elsewhere in London, G4S shed 9.7% and was trading at 243.00 pence per share.

Security company GardaWorld "stands firm" and its 235p per share offer for G4S is final. GardaWorld said early Monday the offer will not be revised.

"There can be no better owner for G4S than GardaWorld, but we are disciplined buyers and we will not overpay for a company with systemic ESG issues that continue to come to light," GardaWorld Chief Executive Stephan Cretier said.

The 235p offer values G4S at GBP3.68 billion.

Earlier in February, London's Takeover Panel stepped in to put in place an auction procedure to resolve an ongoing takeover saga.

Last month, G4S agreed to be taken over by Allied Universal in a GBP3.8 billion deal, but the 245p cash offer has been extended and remains open for acceptances until March 6.

On the AIM market, Avacta rose 15% as it noted press speculation about UK government take-up of its lateral flow SARS-CoV-2 rapid antigen test.

"The company is now progressing to a full clinical validation with a larger number of patient samples in order to obtain a CE mark for the test for professional use, aiming to bring the test to market in Europe around the end of the first quarter of this year," Avacta said.

The biotechnology company added that press reports which stated a saliva-based rapid antigen test is being developed at its Porton Down facility in Wiltshire are incorrect.

Avacta added: "In fact, the evaluated test was the anterior nasal swab test that has subsequently generated the excellent initial clinical performance data.

"We believe an accurate, rapid antigen test, that has been appropriately validated, will help to limit the spread of the coronavirus and support the safe return to work and play. In the UK, the Department of Health & Social Care is a potential customer and partner in the roll out of such a validated test."

Brent oil was quoted at USD63.34 a barrel, down slightly from USD63.47 at the London equities close Friday. Safe-haven gold was quoted at USD1,791.44 an ounce, up from USD1,786.45.

By Eric Cunha; ericcunha@alliancenews.com;

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
1 Sep 2022 12:01

Avacta cancer drug candidate AVA6000 advances to fourth dose cohort

(Alliance News) - Avacta Group PLC said on Wednesday its candidate for multiple forms of cancer, AVA6000 Pro-doxorubicin, is advancing to its fourth dose cohort.

Read more
21 Jul 2022 15:29

Avacta joint venture completes fresh funding round

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Thursday that AffyXell, its joint venture with Daewoong Pharmaceuticals, has completed a funding round to advance its lead mesenchymal stem cell (MSC) programme towards the clinic, and to develop its wider preclinical pipeline of cell therapies.

Read more
21 Jul 2022 12:17

Avacta joint venture completes funding for lead cell therapy programme

(Alliance News) - Avacta Group PLC on Thursday said that its joint venture AffyXell with Daewoong Pharmaceuticals Co Ltd has successfully completed a funding round.

Read more
30 Jun 2022 11:22

Avacta's partner LG Chem renews licence to develop Affimer platform

(Alliance News) - Avacta Group PLC said on Thursday that LG Chem Life Sciences has exercised its renewal option as part of an ongoing collaboration with the company, triggering a fee payment of USD2 million to Avacta.

Read more
29 Jun 2022 11:38

AIM WINNERS & LOSERS: Deltic rises on Shell deal; Windar down on delay

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
29 Jun 2022 10:21

Avacta shares up as cancer drug AVA6000 advances to third dose cohort

(Alliance News) - Avacta Group PLC said on Wednesday its candidate for multiple forms of cancer, AVA6000 Pro-doxorubicin, is advancing to its third dose cohort after "a positive review of the safety data" from the second cohort.

Read more
16 Jun 2022 16:03

UK shareholder meetings calendar - next 7 days

Friday 17 June 
Blackstone Loan Financing LtdAGM
boohoo Group PLCAGM
Directa Plus PLCAGM
Tesco PLCAGM
EnQuest PLCAGM
Octopus Renewables Infrastructure Trust PLCAGM
Monday 20 June 
Armadale Capital PLCAGM
Bank of Georgia Group PLCAGM
Globalworth Real Estate Investments LtdAGM
MetalNRG PLCAGM
Midatech Pharma PLCAGM
Silver Bullet Data Services Group PLCGM re fundraise
Venture Life Group PLCAGM
Tuesday 21 June 
1Spatial PLCAGM
Altus Strategies PLCAGM
Coca-Cola HBC AGAGM
FireAngel Safety Technology Group PLCAGM
HC Slingsby PLCAGM
HSS Hire Group PLCAGM
Mission Group PLCAGM
Novacyt SAAGM
Pendragon PLCAGM
RTW Venture Fund LtdAGM
Velocys PLCAGM
Wednesday 22 June 
ASA International Group PLCAGM
Atalaya Mining PLCAGM
Bonhill Group PLCAGM
Chapel Down Group PLCAGM
Churchill China PLCAGM
Downing Renewables & Infrastructure Trust PLCGM re share issue
Ecofin US Renewables Infrastructure Trust PLCAGM
EJF Investments LtdAGM
Frenkel Topping Group PLCAGM
Good Energy Group PLCAGM
Honeycomb Investment Trust PLCAGM
ICG-Longbow Senior Secured UK Property Debt Investments LtdAGM
Intelligent Ultrasound Group PLCAGM
Iofina PLCAGM
John Wood Group PLCAGM
Kingfisher PLCAGM
LXi REIT PLCGM
Menhaden PLCAGM
North Atlantic Smaller Cos Investment Trust PLCAGM
Pennant International Group PLCAGM
Plant Health Care PLCAGM
Skillcast Group PLCAGM
Team PLCAGM
Tribal Group PLCGM re final dividend
Trident Royalties PLCAGM
Vertu Motors PLCAGM
Wentworth Resources PLCAGM
Thursday 23 June 
Avacta Group PLCAGM
Anglo Asian Mining PLCAGM
Card Factory PLCAGM
Cordiant Digital Infrastructure LtdAGM
Downing Renewables & Infrastructure Trust PLCGM re initial placing & open offer
Eight Capital Partners PLCGM re aligning 2022 bonds with 2026 bonds
GENinCode PLCAGM
Ideagen PLCGM re takeover by Hg Pooled Management Ltd
Longboat Energy PLCAGM
Oxford Nanopore Technologies PLCAGM
Puma VCT 13 PLCGM re cancellation of listing & liquidation
RBG Holdings PLCAGM
Tandem Group PLCAGM
Zinnwald Lithium PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
16 May 2022 14:04

IN BRIEF: Avacta joint venture expands partnership with GenScript

Avacta Group PLC - Cambridge, England-based drug developer and diagnostics company - Says its joint venture AffyXell with Seoul, South Korea-based drug maker Daewoong Pharmaceutical Co Ltd expanded its partnership with GenScript ProBio. Says the partnership covers the process development and production of viral vectors required for the production of AffyXell's future cell therapy products. Adds that GenScript has now committed to take an equity position in AffyXell at a future funding round. The two companies will also collaborate in the area of business development, including potential out-licensing.

Read more
13 Apr 2022 17:33

Avacta increases shareholding in drug developer AffyXell to 22%

(Alliance News) - Avacta Group PLC said on Wednesday it increased its shareholding in its South Korean joint venture, AffyXell Therapeutics.

Read more
13 Apr 2022 13:57

Avacta triggers milestone in Daewoong joint venture

(Sharecast News) - Clinical-stage oncology drug company Avacta announced on Wednesday that a milestone equity payment has been triggered, resulting in an increase in its shareholding in AffyXell Therapeutics.

Read more
8 Apr 2022 16:17

Avacta joint venture enters new immune model collaboration

(Sharecast News) - Clinical-stage oncology drug company Avacta announced on Friday that AffyXell Therapeutics - its joint venture with Daewoong Pharmaceutical - has entered into a collaboration agreement with Chinese biological drugs developer Biocytogen and the Korea Non-Clinical Technology Solution Center (KNTSC).

Read more
8 Apr 2022 11:28

AIM WINNERS & LOSERS: Sensyne Health drops amid AIM delisting warning

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
8 Apr 2022 10:37

Avacta joint venture to collaborate with Chinese biological company

(Alliance News) - Avacta Group PLC said on Friday its joint venture has found a Chinese collaborator to develop new biologic drugs.

Read more
6 Apr 2022 10:23

IN BRIEF: Avacta widens annual loss on research, manufacturing costs

Avacta Group PLC - Cambridge, England-based drug developer and diagnostics company - Posts widened loss in 2021. Pretax loss expands to GBP29.2 million from GBP18.9 million in 2020. However, revenue rises to GBP2.9 million from GBP2.1 million. Like the year before, there will be no dividends.

Read more
16 Mar 2022 13:02

Avacta offloads animal health unit in £2.3m deal

(Sharecast News) - Clinical-stage oncology drug company Avacta Group announced on Wednesday that Vimian Group has acquired its veterinary division, Avacta Animal Health, for consideration of up to £2.3m.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.